Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CPN1 | P15169 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5820507 | 0.87 | MEN1 (0.60) | MEN1KMT2ALMNANPSR1TSHR | |
| SCHEMBL6366834 | 0.86 | MEN1 (0.67) | MEN1KMT2ALMNANPSR1TSHR | |
| SCHEMBL6366838 | 0.86 | MEN1 (0.67) | MEN1KMT2ALMNANPSR1TSHR | |
| SCHEMBL6366829 | 0.86 | MEN1 (0.67) | MEN1KMT2ALMNANPSR1TSHR | |
| SCHEMBL30075866 | 0.85 | MEN1 (0.50) | MEN1KMT2ALMNANPSR1TSHR | |
| SCHEMBL27451392 | 0.85 | MEN1 (0.50) | MEN1KMT2ALMNANPSR1TSHR | |
| SCHEMBL6985765 | 0.83 | MEN1 (0.63) | MEN1KMT2ALMNANPSR1TSHR | |
| SCHEMBL3450850 | 0.83 | MEN1 (0.72) | MEN1KMT2AACP3ALDH1A1TDP1 | |
| SCHEMBL6983317 | 0.83 | MEN1 (0.63) | MEN1KMT2ALMNANPSR1TSHR | |
| SCHEMBL6976406 | 0.83 | MEN1 (0.63) | MEN1KMT2ALMNANPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | ZGENE A/S (DK) | 2007-11-15 | — | — | US | claimed |
| WO-2005079849-A2 | COMPOUNDS FOR ENHANCED CANCER THERAPY | ZGENE A/S (DK) | 2005-09-01 | — | — | WO | claimed |
| US-5883124-A | ADMINISTERING PHENYLACETIC ACID DERIVATIVE AND RETINOID TO TREAT TUMORS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-03-16 | — | — | US | claimed |
| US-5843994-A | Compositions and methods for treating and preventing pathologies including cancer | THE UNITED STATES OF AMERICA AS REPRESENETED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-12-01 | — | — | US | claimed |
| US-5712307-A | Methods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using phemylacetic acids and derivatives therof | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-27 | — | — | US | claimed |
| US-5710178-A | ARYL- AND ARYLOXYALKANOIC ACIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-20 | — | — | US | claimed |
| US-5708025-A | BY INDUCING PRODUCTION OF FETAL HEMOGLOBINS BY ADMINISTERING SPECIFIED ARYL ACIDS, DERIVATIVES, SALTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-01-13 | — | — | US | claimed |
| US-5661179-A | ADMINISTERING; TREATS NEUROBLASTOMA, MYELODYSPLASIA, NON-SMALL CELL LUNG CANCER, PROSTATE CANCER, MELANOMA, BRAIN TUMOR, KAPOSI'S SARCOMA, LYMPHOMA, LEUKEMIA, BREAST AND LUNG CANCER, OSTEOSARCOMA AND FIBROSARCOMA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-26 | — | — | US | claimed |
| US-5654333-A | THERAPY FOR ANEMIA, CANCER, AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-05 | — | — | US | claimed |
| US-5635533-A | ANTITUMOR AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | claimed |
| US-5635532-A | ADMINISTERING PHENYL OR NAPHTHYL ACETIC ACID DERIVATIVES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | claimed |
| US-5605930-A | ADMINISTERING PHENYLACETIC ACID AS AN INHIBITOR OF THE MEVALONATE PATHWAY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-02-25 | — | — | US | claimed |
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | SPERO THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12528837-B2 | Aryl substituted polymyxin derivatives | SPERO THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| CN-118878638-A | Polymyxin compound, pharmaceutical composition and application thereof | 云顶新耀医药科技有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-112789287-B | Compounds of formula (I) | 云顶新耀医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| US-5635532-A | ADMINISTERING PHENYL OR NAPHTHYL ACETIC ACID DERIVATIVES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-06-03 | — | — | US | disclosed |
| US-5605930-A | ADMINISTERING PHENYLACETIC ACID AS AN INHIBITOR OF THE MEVALONATE PATHWAY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0725635-A1 | PHENYLACETATE AND DERIVATIVES ALONE OR IN COMBINATION WITH OTHER COMPOUNDS AGAINST NEOPLASTIC CONDITIONS AND OTHER DISORDERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995010271-A2 | PHENYLACETATE AND DERIVATIVES ALONE OR IN COMBINATION WITH OTHER COMPOUNDS AGAINST NEOPLASTIC CONDITIONS AND OTHER DISORDERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528837-B2 | Aryl substituted polymyxin derivatives | PTMS, PNISR, BCAT2 | MEN1 4574/4885KMT2A 1522/4885LMNA 1707/4885 |
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | PTMS, FPR1, BCAT2 | MEN1 4442/4885KMT2A 1543/4885LMNA 2367/4885 |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | TYMP, BAD, NUDT1 | MEN1 2022/4885KMT2A 395/4885LMNA 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.